Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 95
Issues in Risk Assessment Appendix D Workshop Program Thursday, September 6, 1990 Lecture Room, National Academy of Sciences 2101 Constitution Ave., NW Washington, DC 9:00 Introduction and Objectives: Kenny Crump, Clement Associates; Chairman 9:15 Definition and Application of MTD Presenter: Eugene McConnell, Raleigh, NC 9:45 Discussants: John Emmerson, Eli Lilly and Co.; Ian Munro, University of Guelph 10:05 Questions and Comments 10:15 Break 10:30 Correlations between the MTD and Measures of Carcinogenic Potency: Implications for Risk Assessment Presenter: Daniel Krewski, Health and Welfare Canada 11:15 Discussants: Kenny Crump, Clement Associates; Lauren Zeise, California Department of Health Services; Thomas Starr, Environ Corp.;
OCR for page 96
Issues in Risk Assessment Edmund Crouch, Cambridge Environmental, Inc. 12:00 Questions and Comments 12:30 Lunch 2:00 What are Bioassays Conducted at the MTD Telling Us? Presenter: Bruce Ames, University of California, Berkeley 2:45 Discussants: Michael Gallo, University of Medicine and Dentistry of New Jersey; David Gaylor, National Center for Toxicological Research 3:15 Questions and Comments 3:30 Break 3:45 General Discussion Leader: Kenny Crump, Clement Associates Issues: • The basis of the observed correlation between the MTD and measures of carcinogenic potency • The possible influence on biological processes of dosing at this level • The implications for the design of rodent bioassays • The implications for carcinogenic risk assessment 5:00 Adjourn